Published in Hepatology on November 01, 2002
Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years | NCT03764345
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Liver cirrhosis. Lancet (2008) 6.11
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84
Current management strategy of hepatocellular carcinoma. World J Gastroenterol (2009) 1.79
Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest (2009) 1.75
Viral hepatocarcinogenesis. Oncogene (2010) 1.73
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med (2012) 1.71
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf (2009) 1.61
Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med (2008) 1.61
Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology (2010) 1.55
SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med (2004) 1.46
Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut (2005) 1.34
Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol (2009) 1.31
Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol (2008) 1.28
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol (2010) 1.25
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology (2011) 1.25
Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol (2011) 1.24
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis (2004) 1.20
Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer (2008) 1.19
Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol (2009) 1.18
Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol (2011) 1.17
Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon (2014) 1.17
Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis (2009) 1.15
Hepatocellular carcinoma in the world and the middle East. Middle East J Dig Dis (2010) 1.07
Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One (2013) 1.06
Management of chronic hepatitis C. Postgrad Med J (2005) 1.03
The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Br J Cancer (2006) 1.02
Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int (2010) 1.02
Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence (2012) 1.01
Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 0.98
Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) (2005) 0.97
Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol (2012) 0.96
A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol (2011) 0.96
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol (2012) 0.96
Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med (2009) 0.95
Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. Electrophoresis (2013) 0.94
Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest. Cancer Res (2010) 0.94
First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. World J Hepatol (2011) 0.92
Reversal of liver fibrosis. Saudi J Gastroenterol (2009) 0.90
Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation (2009) 0.90
Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer (2011) 0.90
The prevalence of hepatitis C virus infection in Texas: implications for future health care. Proc (Bayl Univ Med Cent) (2005) 0.89
Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol (2011) 0.88
Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88
Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol (2009) 0.87
Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Med Sci Monit (2013) 0.87
Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report. Am J Case Rep (2015) 0.86
Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat (2009) 0.85
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J (2011) 0.85
Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. Dig Dis Sci (2010) 0.85
Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. Cancer Cell Int (2011) 0.85
Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C. Hum Vaccin Immunother (2013) 0.84
Considerations for two inoculation methods of rabbit hepatic tumors: Pathology and image features. Exp Ther Med (2011) 0.84
Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci (2014) 0.83
Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. World J Hepatol (2015) 0.83
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Association of laboratory parameters with viral factors in patients with hepatitis C. Virol J (2011) 0.83
De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy. Dig Dis Sci (2006) 0.83
Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett (2016) 0.81
Evaluation of metabolite biomarkers for hepatocellular carcinoma through stratified analysis by gender, race, and alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev (2013) 0.81
Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother (2012) 0.81
The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma. J Clin Virol (2011) 0.81
Peroxisome proliferator-activated receptors in HCV-related infection. PPAR Res (2009) 0.81
Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg (2006) 0.80
Less-established risk factors are common in Asian Americans with hepatitis C virus: a case-controlled study. Dig Dis Sci (2013) 0.80
Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier. World J Gastroenterol (2006) 0.80
HCV genotype-specific correlation with serum markers: higher predictability for genotype 4a. Virol J (2011) 0.80
Pathogen-driven gastrointestinal cancers: Time for a change in treatment paradigm? Infect Agent Cancer (2012) 0.80
Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent. Biologics (2010) 0.80
Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients. World J Gastroenterol (2008) 0.79
Claudin-1 required for HCV virus entry has high potential for phosphorylation and O-glycosylation. Virol J (2011) 0.79
Comparison of magnetic resonance elastography and diffusion-weighted imaging for staging hepatic fibrosis. Chin Med J (Engl) (2015) 0.79
Simultaneous occurrence of a hepatocellular carcinoma and a hepatic non-Hodgkin's lymphoma infiltration. World J Hepatol (2010) 0.78
Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease. Dig Dis Sci (2007) 0.78
Diagnostic Accuracy of 2D-Shear Wave Elastography for Liver Fibrosis Severity: A Meta-Analysis. PLoS One (2016) 0.78
Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med (2011) 0.78
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. J Transl Med (2012) 0.78
Relationship of α-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis. Exp Ther Med (2012) 0.77
Long-term survival after chemoembolization of metastatic right atrial tumor thrombus as a presenting feature of hepatocellular carcinoma: A case study. Oncol Lett (2012) 0.77
Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice. PLoS One (2014) 0.77
Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis. Exp Ther Med (2014) 0.77
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol (2015) 0.77
TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells. Int J Nanomedicine (2014) 0.77
Sustained eradication of hepatitis C virus by low-dose long-term interferon therapy in a renal transplant recipient with dual infection with hepatitis B and C viruses: a case report. J Med Case Rep (2011) 0.76
Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C. J Gastroenterol (2007) 0.76
Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.76
Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts. Semin Intervent Radiol (2015) 0.75
Review. Gastroenterol Hepatol (N Y) (2006) 0.75
c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease. Genes (Basel) (2017) 0.75
Development and Application of an In-house Line Probe Assay for Hepatitis C Virus Genotyping. Hepat Mon (2013) 0.75
Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response. World J Gastroenterol (2010) 0.75
Is exposure to Agent Orange a risk factor for hepatocellular cancer?-A single-center retrospective study in the U.S. veteran population. J Gastrointest Oncol (2016) 0.75
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. ISRN Hepatol (2014) 0.75
Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. BMC Gastroenterol (2016) 0.75
Identification of the transcripts associated with spontaneous HCV clearance in individuals co-infected with HIV and HCV. BMC Infect Dis (2016) 0.75
Interleukin-17F expression is elevated in hepatitis C patients with fibrosis and hepatocellular carcinoma. Infect Agent Cancer (2017) 0.75